Bal Pharma share news, announcements and annual reports
NSE: BALPHARMABSE: 524824Pharmaceuticals & BiotechnologySmall Cap
Bal Pharma Limited · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Apr 1995 on BSE, May 2006 on NSE
Last close ₹81.85down ₹2.76 (3.26%)BSE ₹81.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹84.61.
30 Oct: open ₹84.05, high ₹84.05, low ₹81.21
52-week range of traded prices to 30 Oct 2026
₹60.00Low, 30 Mar 2026₹124.60High, 10 Sep 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹130 Cr2,779th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 18.08
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 1.58
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.47%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 9.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 1.94
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,401
Bal Pharma share news and announcements
549 announcements, routine notices left out, newest first. Page 10 of 11.
Apr 2014
2 Apr · Updates
Ms. Hasumati Pravin Siroya who was part of the promoter group of the Company by holding 2,83,500 equity shares of Rs. 10 each constituting 2.55% of the paid up capital of the Company, has opted to exit herself from the promoter group of the Company, citing personal reasons. The Board of Directors of the Company after reviewing the request of Ms. Hasumati Pravin Siroya has noted/agreed to offer her an exit from the promoter group with immediate effect. Ms. Hasumati Pravin Siroya's share holding in the Company will hence forth be reclassified as public holding in the Clause 35 report.
Feb 2014
17 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 12, 2014 has transacted the following business:(1) After having received the full consideration amount of Rs. 21/- per equity share, the Board has made the allotment of 5,37,764 equity shares of Rs. 10 each to Anita Siroya, on preferential basis. With this allotment, the paid up capital of the Company is enhanced to 1,11,11,388 equity shares of Rs. 10 each.12 Feb · Results
Jan 2014
Nov 2013
12 Nov · Results
Oct 2013
30 Oct · Board meeting
Board of Directors inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2013.
Sep 2013
Aug 2013
Jul 2013
22 Jul · Board meeting
Inter-alia, to take on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2013.3 Jul · Meeting
Company has fixed Book Closure from September 16, 2013 to September 18, 2013 for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on September 18, 2013.
May 2013
28 May · Dividend
Board of Directors of the Company at its meeting held on May 27, 2013 has recommended payment of dividend of Re.0.75/- (7.5%) per equity share of Rs.10 each.27 May · Results
8 May · Board meeting
Inter alia, will be transacting the following: (1) To consider and approve the Audited Financial Results of the Company for the financial year ended March 31, 2013 (2) Recommendation of Dividend, if any (3) Approve the audited accounts of the Company for the FY ended March 31, 2013 along with the notice of A.G.M., Director s Report and Corporate Governance Report (4) To decide on the book closure and A G M date.
Feb 2013
Jan 2013
Nov 2012
2 Nov · Board meeting
Board of Directors inter alia will be taking on record and approve the Un-Audited Financial Results of the Company for the quarter and half year ended September 30, 2012.
Oct 2012
16 Oct · Business
Based on the approval obtained from the Shareholders & Stock Exchanges, the Board of Directors of Bal Pharma Limited, Bangalore will consider the issue and allotment of 22,98,748 warrants on preferential basis to the promoters and strategic investors on 19.10.2012
Sep 2012
Aug 2012
13 Aug · Meeting
Board of Directors of the Company at its meeting held on August 13, 2012 has decided to close the Register of Members and Share Transfer Books of the Company from September 19, 2012 to September 21, 2012 (Both days inclusive) and convene the Annual General Meeting of the Company on September 21, 2012.13 Aug · Board meeting
Board of Directors of the Company at its meeting held on August 10, 2012 has proposed the allotment of 22,98,748 warrants convertible into 22,98,748 equity shares of Rs.10 each of the Company on preferential basis to the promoters and to strategic investors. This proposal is subject to the approval of the share holders at the ensuing Annual General Meeting of the Company.10 Aug · Results
10 Aug · Results
1 Aug · Board meeting
Inter alia will transact the following business : (1) Take on record and approve the Un-Audited financial results of the Company for the quarter ended June 30, 2012; (2)Take on record and approve the Audited financial results of the company for the financial year ended March 31, 2012; (3) Propose issue and allotment of warrants on preferential basis to the promoters and to strategic investors, subject to the approval of the members; (4) Approve the audited accounts of the Company for the F.Y ended March 31, 2012 along with the notice for AGM, Directors Report and Corporate Governance Report; (5) Decide on the book closure date and AGM date.
Jul 2012
26 Jul · Management
Vide letter dated July 26, 2012 that Mr.Venkatesan Murali is appointed as General Manager Finance and Company Secretary of the Company. Mr. Venkatesan Murali is also designated as the Compliance officer of the Company.
May 2012
11 May · Board meeting
Board of Directors of the Company at its meeting held on May 10, 2012 has noted appointment of Mr. M P George as Chief Operating Officer of the Company and has appointed Mr. Promod Kumar, as independent Director of the Company in place of Mr. Arun Bhan, ex-Independent Director of the company who has resigned from the Board due to his nominations in United Nations agencies in Ireland.11 May · Results
Apr 2012
30 Apr · Board meeting
To consider, and take on record, interalia, the Unaudited Financial Results (UFR) for the 4th quarter ended on, March 31, 2012.
Feb 2012
4 Feb · Board meeting
Board of Directors of the Company at its meeting held on February 03, 2012, has accepted resignation rendered by Mr. Arun Bhan, Independent Director of the Company due to his nominations in United Nations agencies in Ireland and the Company is in the process of appointing a suitable one place of him.
Jan 2012
23 Jan · Board meeting
To consider, and take on record, the Unaudited Financial Results (UFR) for the third quarter, ended on, December 31, 2011.16 Jan · Purchase of Shares
Mrs. Anita Siroya, a share holder, belonging to promoters category has informed on January 13, 2012 purchased 10,000 (ten thousand only/-) equity shares of Bal Pharma Limited, on January 05, 2012 @ market price of Rs.16.90/- (Rupees sixteen and ninety Paise only) per equity share. The Company has taken the information on record. Holding of Mrs. Anita Siroya, as on date is 480,776 equity shares (470,776 + 10,000).
Nov 2011
Oct 2011
24 Oct · Board meeting
To consider, and take on record, the Unaudited Financial Results (UFR) for the 2nd Quarter ended on September 30, 2011.17 Oct · Business
Company has allotted 90,400 equity shares at par value of Rs.10/- each to exercise the ESOP Options granted to the eligible employees of the Company, under Bal Pharma ESOP Scheme, 2006.
Sep 2011
23 Sep · Meeting
Annual General Meeting of the Company was held on September 21, 2011, as scheduled, Ordinary Resolutions approving the followings were passed at the meeting : (1) The audited Balance Sheet as at March 31, 2011 and Profit and Loss Account for the year ended on that date, together with the Directors' Report and Auditor's Report was adopted; (2) Mr. Arun Bhan was re-appointed as independent Director; (3) Dr.S.Prasanna was re-appointed as Executive Director; (4) Messrs TD Jain & DI Sakaria (erstwhile M/s Ostawal & Jain,) Auditors of the Company was reappointed and was authorized the Board of Directors to fix their remuneration.
Aug 2011
19 Aug · Meeting
Annual General Meeting of the Company will be held on September 21, 2011. The Register of Members and the Share Transfer Books will remain closed on September 21, 2011 for the purpose of the Annual General Meeting of the Company.12 Aug · Management
Mr. D. Muarali has been appointed as the Company Secretary & Compliance Officer, in place of Mr. S. Ramji who has resigned from the Company on personal grounds. Mr.D. Muarali, will be the Chief Financial Officer of the Company.
Jul 2011
27 Jul · Board meeting
To consider and take on record, the Audited Financial Results of the Company for the entire financial year ended March 31, 2011, Unaudited Financial Results (UFR) for the first quarter ended June 30, 2011 and to discuss the AGM related matters.
May 2011
13 May · Management
Mr. Ajit Kumar has been appointed as the new Nominee Director of the Export Import Bank of India on the Board in place of Mr. David Rasquinha who has been resigned from the Directorship as part of the rotation policy of the Export Import Bank of India.5 May · Results
Bal Pharma Limited had informed the Exchange regarding a Board meeting to be held on May 13, 2011 to consider, and take on record, the Audited Financial Results of the Company (Instead of 4th quarter unaudited Financial Results) for the entire financial year ended on March 31, 2011. The Company has now informed the Exchange that due to unavoidable reasons, it has been decided to place, instead of audited accounts, unaudited accounts of the Company for the 4th quarter ended on March 31, 2011 before the meeting of the Board of Directors of the Company and publish the same on or before May 15, 2011.
Apr 2011
28 Apr · Board meeting
To consider, and take on record, the Audited Financial Results of the Company (Instead of 4th quarter unaudited Financial Results) for the entire financial year ended on March 31, 2011.
Jan 2011